CLINICAL_TRIALS
trial_result
· 2025-10-20
Clinical Trial Update: BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia [Phase 2]
Summary
Phase 2 trial results for the BRAF inhibitor vemurafenib in relapsed or refractory hairy cell leukemia have been completed and posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Hairy Cell Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2025-10-20